135.50 -0.19 (-0.14%)
After hours: 7:18PM EST
|Bid||135.50 x 900|
|Ask||135.86 x 1000|
|Day's Range||135.63 - 136.29|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||24.20|
|Forward Dividend & Yield||3.60 (2.68%)|
|1y Target Est||N/A|
NEW BRUNSWICK, N.J. , Feb. 14, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28 th , at Lotte New York ...
NEW BRUNSWICK, N.J., Feb. 13, 2019 /PRNewswire/ -- Focused on creating the next frontier of surgery, Johnson & Johnson (JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures.
NEW BRUNSWICK, N.J. , Feb. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2019 CAGNY Conference on Tuesday, Feb. 19 , at The Boca Raton Resort, Boca Raton , FL. Alison Lewis ...
TECNIS Eyhance IOL is the latest innovation in the industry leading TECNIS® Family of Intraocular Lenses First lens (1) in the monofocal IOL category in Europe to deliver improved intermediate vision and ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61 Adjusted 2018 Fourth-Quarter EPS was $1.97 , an increase ...
NEW ORLEANS , Jan. 18, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
NEW BRUNSWICK, N.J., Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new heart health program using an app from Johnson & Johnson in combination with Apple Watch's irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes of the 33 million people worldwide living with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications.
NEW BRUNSWICK, New Jersey, Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share. Johnson & Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the Company from the Tokyo Stock Exchange. The Company, which markets the DR.
Zamansky LLC investigates Johnson & Johnson Inc. (JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Savings Plan (the “Plan”). Zamansky LLC is a leading stock law firm with a practice in securities fraud, ERISA and employment class actions.
NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 ...
NEW BRUNSWICK, N.J., Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (4924.T) (the "Company") not already held by Johnson & Johnson or its affiliates that was previously announced on October 23, 2018, have been satisfied and the offering period for the tender offer has expired.
NEW BRUNSWICK, N.J. , Jan. 10, 2019 /PRNewswire/ -- Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated ...
NEW YORK, NY / ACCESSWIRE / January 4, 2019 / U.S. markets plunged on Thursday, with the Dow Jones falling more than 600 points, as fears of a possibility of a global economic slowdown intensified after Apple lowered revenue forecasts. The Dow Jones Industrial Average dropped 2.83 percent to close at 22,686.22, dragged mostly lower by losses in Apple’s stock, while the S&P 500 Index decreased 2.48 percent to close at 2,447.89. The Nasdaq Composite Index slumped 3.04 percent to close at 6,463.50.
NEW BRUNSWICK, N.J., Jan. 2, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2019 of $0.90 per share on the company's common stock. The dividend is payable on March 12, 2019 to shareholders of record at the close of business on February 26, 2019. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
Zamansky LLC investigates Johnson & Johnson Inc. (JNJ) (“J&J” or the “Company”) on behalf of its current and former employees for potential violations of the federal Employee Retirement Income Security Act (“ERISA”) in the J&J Retirement Savings Plan (the “Plan”).
NEW BRUNSWICK, N.J. , Dec. 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 37 th Annual JP Morgan Health Care Conference on Monday, Jan. 7 th , at the Westin St. Francis ...
The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes. A replay of the conference call will be available until approximately 12:00 a.m. on January 30, 2019.
NEW BRUNSWICK, N.J., Dec. 17, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. Johnson & Johnson reaffirms its full-year 2018 sales and adjusted earnings per share guidance of $81.0 to $81.4 billion and $8.13 to $8.18 per share, respectively.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Both Johnson & Johnson and Idera Pharmaceuticals were big losers in Friday’s trading session. J&J tumbled on a Reuters story that alleged it knew about its baby powder having asbestos for decades while Idera announced data from an ongoing phase 2 trial that were actually encouraging. Johnson & Johnson shares were tanking on Friday, on a Retuers story that the company had known for decades that its baby powder has asbestos.
NEW YORK, Dec. 14, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Johnson & Johnson (NYSE: JNJ). Our investigation concerns whether.
SAN FRANCISCO , Dec. 14, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP notifies investors in Johnson & Johnson (NYSE: JNJ) of the Firm's investigation of possible disclosure violations. If you ...
Zamansky LLC announces that it has commenced an investigation of Johnson & Johnson Inc. (JNJ) (“J&J”) on behalf of its current and former employees over the J&J Retirement Savings Plan (the “Plan”) for potential violations of the federal Employee Retirement Income Security Act (“ERISA”). ERISA imposes fiduciary duties to prudently manage and invest plan assets.